Milestone Pharmaceuticals
Biotechnology Research • 
Montreal, Quebec, Canada • 51-100 Employees
Company overview
| Headquarters | 1111 Dr. Frederik-Philips, Montreal, QC H4M 2X6, CA |
| Phone number | +15143360444 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Founded | 2007 |
| Employees | 51-100 |
| Socials |
Key Contacts at Milestone Pharmaceuticals
Anthony Marchese
Associate Director, Scientific Communications
Andrew Saik
Director
Stephen Skinner
Regional Sales Director - West
Seth Fischer
Board Director
Silvia Shardonofsky
Medical Director
Joe Ferrante
Senior Director Market Access
James Nuñ Pharmd
Senior Director, Head Of Medical Excellence & Head Of Field-Based Medicine
Rick Sherwood
Sr. Director, Commercial Strategy & Execution
Jason Farley
Regional Sales Director - East
Matt Jones
Associate Director, Accounting
Milestone Pharmaceuticals Email Formats
Milestone Pharmaceuticals uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@milestonepharma.com), used 56.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@milestonepharma.com | 56.6% |
{first name}{last name} | johndoe@milestonepharma.com | 18.9% |
{first initial}.{last name} | j.doe@milestonepharma.com | 11.3% |
{last name}{last name} | doedoe@milestonepharma.com | 9.4% |
{first initial}{second initial} | jo@milestonepharma.com | 1.9% |
About Milestone Pharmaceuticals
Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page. https://milestonepharmaceuticals.applytojob.com/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.
Milestone Pharmaceuticals revenue & valuation
| Annual revenue | $18,500,000 |
| Revenue per employee | $273,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $59,200,000 |
| Total funding | $193,300,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Milestone Pharmaceuticals has 32 employees across 10 departments.
Departments
Number of employees
Funding Data
Explore Milestone Pharmaceuticals's funding history, including investment rounds, total capital raised, and key backers.
Milestone Pharmaceuticals Tech Stack
Discover the technologies and tools that power Milestone Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
UI frameworks
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Miscellaneous
Programming languages
Blogs
JavaScript graphics
United Kingdom
Switzerland
Germany
Frequently asked questions
4.8
40,000 users
